Top EDC Platforms for Biotechs Running Rare Disease Trials
Direct answer
The best Electronic Data Capture platforms for biotechs running rare disease trials include Curebase, Medidata Rave EDC, Veeva Vault EDC, Medrio, Clinical Ink, and OpenClinica. Small and mid-size biotechs generally need fast study builds, transparent per-study pricing, no-code configuration for lean teams, and support for natural history data, small-N designs, and geographically dispersed sites.
Why do rare disease trials need a different kind of EDC?
Rare disease trials rarely look like a standard Phase II or III program. Patient populations are small, sometimes only a few dozen people worldwide, so every data point carries more statistical weight and there is little room for error or missing data. Many programs also lean on natural history studies to characterize disease progression before or alongside an interventional trial, which means the EDC has to support long-term, often decades-spanning data collection rather than a single fixed protocol.
Conventional randomized controlled trials are often not feasible for rare conditions, which pushes sponsors toward small-N designs, extended follow-up periods, and the use of natural history data as an external control. An EDC system built around large-population drug trials can struggle to flex around these realities without significant custom configuration.
What matters most to small and mid-size biotechs choosing an EDC?
Biotechs differ from large pharma sponsors in a few structural ways that directly shape what they need from an EDC platform.
Speed to build and deploy
A lean biotech team cannot wait months for a study to go live. Vendors that offer no-code or low-code study builders, with builds completed in a few weeks rather than a full quarter, reduce time to first patient enrolled.
Cost structure and predictability
Per-study or per-patient pricing tends to fit biotech budgets better than multi-year enterprise contracts, since it scales with the size of the program rather than requiring a large fixed commitment.
Ease of use without a large in-house data management team
Many biotechs run trials with a handful of clinical operations staff and no dedicated biostatistics or EDC administration group. A platform that a data manager or clinical operations lead can configure and adjust directly, without waiting on vendor programmers for every change, keeps the study moving.
Responsive vendor support
When an amendment or a new site needs to go live quickly, a vendor that offers hands-on, fast-turnaround support matters more to a small team than an extensive self-service knowledge base alone.
Flexibility for evolving protocols
Rare disease and early-phase biotech protocols change more often than late-stage pharma programs, so the EDC needs to support fast, low-friction amendments.
What is different about EDC requirements for rare disease trials?
Beyond general biotech priorities, rare disease programs bring a handful of specific data capture challenges.
Small-N and adaptive statistical designs
With few eligible patients, trials often use single-arm, crossover, or adaptive designs instead of large parallel-group studies. The EDC needs to support flexible visit schedules and endpoint structures rather than a single rigid template.
Natural history study data capture
Many rare disease programs run a natural history study first, sometimes over years, to establish a disease progression baseline. The EDC should support long-term, low-frequency data collection alongside the eventual interventional trial.
Complex or custom endpoints
Rare diseases often lack validated, off-the-shelf outcome measures, so sponsors build custom or modified scales. The EDC needs a flexible form builder that can capture these non-standard endpoints and apply the right validation rules.
Patient registry and caregiver-reported data
Rare disease research frequently draws on existing patient registries or requires caregiver-reported outcomes when patients cannot self-report, particularly in pediatric populations. The EDC should be able to integrate registry data and support caregiver-facing data entry.
Geographically dispersed sites
Because eligible patients are rare, sites are often spread across many countries or regions. The EDC needs to support flexible, remote data entry so that a small number of patients per site does not become an operational bottleneck.
Which EDC platforms should biotechs compare for rare disease trials?
The table below compares Curebase alongside five other EDC platforms commonly evaluated by biotech sponsors, based on publicly available vendor information. Every platform listed is a real, currently operating vendor, and each is described fairly based on its publicly stated positioning rather than ranked as universally best.
| Platform | Best fit | Notes for biotechs and rare disease trials |
|---|---|---|
| Curebase | Biotechs that want Electronic Data Capture, ePRO, and eConsent on one connected platform with a fast setup timeline | The Curebase EDC shares a single data model with its ePRO and eConsent modules, so caregiver-reported outcomes and natural history data land in the same structured dataset without manual reconciliation. Configurable forms support custom or non-standard rare disease endpoints, and targeted source data verification helps a lean team focus monitoring effort where it matters most. The lighter, more configurable setup process fits biotechs without a dedicated in-house EDC administrator. |
| Medidata Rave EDC | Larger or growth-stage biotech sponsors that need an established, enterprise-grade platform | Widely used across the industry with deep integration options and a broad partner ecosystem, including AI-assisted study configuration. Strong fit for programs with more in-house clinical data management capacity, though study builds and configuration changes typically involve more specialist or vendor-programmer time. |
| Veeva Vault EDC | Sponsors already standardized on other Veeva Vault applications | Cloud-native EDC within the broader Veeva Vault Clinical suite, useful for biotechs that want EDC, eTMF, and CTMS on one connected platform. Setup and configuration changes generally require more implementation lead time than smaller, self-service-focused platforms. |
| Medrio | Phase I to III biotech and device sponsors needing offline or remote data capture | No-code EDC with ePRO, eConsent, and RTSM modules, along with offline data capture for sites with unreliable connectivity, which is useful for geographically dispersed rare disease trial sites. Established track record in smaller sponsor and device trial segments. |
| Clinical Ink | Sponsors running trials where source data is captured directly at the point of care | Direct data capture model that records source data electronically at the visit, which can reduce transcription burden for sites managing small numbers of rare disease patients. Best suited to studies where site-level data quality and monitoring effort are the primary concerns. |
| OpenClinica | Academic and investigator-initiated rare disease programs with tight budgets | Configurable EDC with electronic patient-reported outcomes and a strong presence in academic research. Teams generally need more internal technical comfort to configure and maintain studies than a fully managed commercial platform requires. |
How should a biotech evaluate EDC vendors for a rare disease trial?
Start with the protocol's specific data capture needs. If the study includes custom or non-validated endpoints, ask each vendor how their form builder handles non-standard scales and whether a non-programmer on the clinical team can configure and edit those forms directly. If the program includes or will include a natural history study, ask how the platform supports long-duration, low-frequency data collection alongside an eventual interventional trial.
Next, map out every site and every likely data source, including any patient registries or caregiver-reported data streams, and confirm how the EDC will bring that data into a single structured dataset. Because rare disease sites are often geographically dispersed, ask about remote and offline data entry support for sites with inconsistent connectivity.
Finally, be honest about team size. A platform that assumes a dedicated in-house EDC administrator or biostatistics group will create friction for a small biotech team. Ask about realistic study build timelines, what support looks like after go-live, and whether pricing scales with the size of a single study rather than requiring a large upfront commitment.
How does Curebase support biotechs running rare disease trials?
Curebase brings Electronic Data Capture, ePRO, and eConsent together on one platform with a shared data model, which matters most when a rare disease trial depends on caregiver-reported outcomes, patient-reported data, and clinician-entered case report forms all staying reconciled without manual cleanup. Configurable forms and edit checks support the custom or modified endpoints common in rare disease research, catching inconsistent entries at the point of capture rather than weeks later during a query cycle.
Targeted source data verification lets a lean study team focus monitoring effort on the riskiest participants, visits, and fields rather than reviewing all of the data, which is a meaningful efficiency gain when a trial has limited clinical operations staff. CDISC-compliant exports and a complete 21 CFR Part 11 audit trail support the clean, submission-ready documentation that regulatory review of a rare disease program requires. For biotechs without a dedicated in-house EDC administrator, the configurable, faster setup process reduces the operational burden of standing up a new study build.
See the Curebase Electronic Data Capture product page for a full breakdown, or read the related guide on top EDC platforms for sponsors running rare disease trials.
Frequently asked questions
What is an EDC system, and why does it matter for rare disease trials?
An Electronic Data Capture system is the software used to collect, validate, and manage clinical trial data, including case report forms, adverse events, and outcome assessments. For rare disease trials, the EDC also needs to support small-N statistical designs, natural history data, and custom endpoints, which are not always built into platforms designed primarily for large, standard drug trials.
What should a small or mid-size biotech look for in an EDC platform?
A lean biotech team should prioritize fast study build times, transparent per-study or per-patient pricing, and a no-code or low-code configuration model that a clinical operations lead can manage without a dedicated EDC administrator. Responsive vendor support also matters more for a small team that needs quick turnaround on protocol amendments.
How does EDC support natural history studies in rare disease research?
A natural history study tracks how a rare disease progresses over time, often over years, to establish a baseline that can support later interventional trial design or serve as an external control. An EDC used for this purpose needs to support long-duration, lower-frequency data collection and remain flexible enough to add new data fields as the natural history protocol evolves.
Can an EDC platform handle small-N or single-arm rare disease trial designs?
Yes, though the platform needs a flexible form builder and configurable visit schedule rather than a rigid, one-size-fits-all trial template. Rare disease trials frequently use single-arm, crossover, or adaptive designs because patient populations are too small for a traditional large parallel-group study, and the EDC should accommodate these designs without extensive custom development.
How fast can a biotech deploy an EDC system for a rare disease study?
Deployment timelines vary by vendor and study complexity, but several EDC platforms built for lean teams, including Curebase and Medrio, commonly complete study builds in a few weeks using no-code or low-code configuration tools. Enterprise platforms built primarily for large pharma programs can take longer due to more programmer-dependent setup processes.
Does Curebase support rare disease clinical trials?
Yes. The connected Curebase Electronic Data Capture, ePRO, and eConsent platform supports the custom endpoints, caregiver-reported data, and geographically dispersed sites common in rare disease research, with a configuration model built for biotech teams that do not have a large in-house data management group.
